Oracle and AstraZeneca partnership to look at how artificial intelligence (AI) and real-world data can drive healthcare innovation. The companies will also look at ways to help clinicians to identify patients who are eligible for clinical trials. They also want to speed up evidence generation and translate relevant research insights into everyday care. This collaboration will bring together AstraZeneca’s scientific and therapeutic expertise with Oracle’s health data, cloud, AI, analytics and clinical workflow capabilities.
Oracle has joined forces with AstraZeneca to investigate new applications of artificial intelligence and real-world health care data. The initiative will explore ways to improve clinical research and to promote evidence-based decision-making in healthcare. Also, the companies want to connect scientific findings to practical application in patient care.
Under the non-binding agreement, Oracle and AstraZeneca will assess selected use cases. Such applications may make clinical trials more efficient and more likely to be successfully recruited. Modern applications and artificial intelligence (AI) technologies could enable healthcare teams to identify eligible patients earlier and more efficiently. That way more patients can be offered clinical trials that meet their medical needs.
Patient recruitment remains one of the major challenges facing clinical trials. Therefore, the collaboration will explore ways to address this obstacle through data-driven approaches. The initial areas of interest could include oncology, cardiovascular, renal and metabolic diseases. Respiratory conditions, immunology, and rare diseases may also form part of the exploration.
Pascal Soriot, Chief Executive Officer, AstraZeneca said: “This unique collaboration brings leaders in healthcare and AI together at a global scale to accelerate the journey from the discovery of medicine to patient care. Combining AstraZeneca’s world class science with Oracle’s deep data and technology expertise, we can help clinicians identify patients sooner, optimize clinical trials, and generate evidence continuously across the lifecycle of a medicine.”
Advancing Clinical Research Through AI
The collaboration reflects growing interest in applying AI to healthcare research and clinical decision-making. In particular, better use of health data could help researchers identify suitable participants for clinical studies. It could also support faster evidence generation throughout a medicine’s development and use.
“Some of the most important opportunities for AI are in healthcare, where better use of data can help turn scientific innovation into better outcomes for patients,” noted Mike Sicilia, chief executive officer, Oracle. “By bringing AstraZeneca’s scientific expertise together with Oracle’s data, cloud, AI, and healthcare capabilities, we have an opportunity to help accelerate research, connect more patients to clinical trials, and ultimately bring relevant insights into care faster.”
Through this initiative, both companies intend to explore how healthcare technology can connect research findings with clinical practice. Moreover, their combined capabilities could help care teams access relevant information when making treatment decisions.
Connecting Research and Patient Care
Anne-Claire Gerbaldi, Chief Digital, Data and AI Officer, AstraZeneca, added: “Too many patients are diagnosed late or face a long journey to get the care they need. To build the next decade of medicine, we aim to harness AI to connect learnings across science, clinical trials, and everyday care, generating insights that continuously strengthen research, accelerate innovation, and enhance patient outcomes. Bringing together the unique capabilities of Oracle and AstraZeneca, we believe we can support smarter clinical trials, strengthen safety monitoring, and help ensure patients are diagnosed sooner and receive the right care.”
The partnership will also look at how to better link scientific research to the delivery of routine healthcare. Companies will look at data and research that is relevant to help improve the design of clinical trials and safety oversight. Moreover, these efforts may help healthcare professionals in earlier patient recognition and proper care.
Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences, said: “Healthcare progress depends on shortening the distance between scientific insight and the decisions clinicians make every day. AstraZeneca brings deep scientific and therapeutic expertise, and Oracle will deliver the secure data, cloud, AI, and clinical workflow capabilities. This collaboration has the potential to help health systems identify eligible patients sooner, broaden access to clinical trials, and generate evidence that supports the next decision, all under the governance of the health systems delivering care.”
The companies recognize the importance of connecting scientific evidence with everyday clinical decisions. Therefore, the collaboration will examine how secure technology and clinical workflow tools could support healthcare organizations. These capabilities may help health systems identify eligible patients, expand trial participation, and use research evidence more effectively.
Creating a Continuous Learning Model
Oracle and AstraZeneca also plan to explore a model of continuous learning. Thus, results from clinical research and routine care could be applied to inform future study designs, safety monitoring, and patient care. Thus, findings from health care practice could inform future research and clinical development. Also, the companies plan to develop joint governance models and reusable technical blocks. They also intend to identify outcome measures to assess the results of the initiative. Such measures will help the organizations evaluate the effectiveness of their proposed approaches.
The results will help Oracle and AstraZeneca determine whether successful applications can be extended to other disease areas and countries. But the collaboration is still exploratory under the non-binding agreement. In general, the Oracle and AstraZeneca partnership will explore how healthcare innovation can be aided by AI, real-world data, cloud technology and clinical expertise. The companies are linking research with clinical practice to improve access to clinical trials, speed up evidence generation and provide healthcare professionals with relevant insights. The initiative will investigate potential uses in a number of disease areas, and assess opportunities for wider adoption.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: PRNewswire
